Background: Osteosarcoma (OS) is a highly aggressive bone malignancy with limited treatment options and poor prognosis. This exploratory study aimed to identify molecular subtypes of early-stage, treatment-naive OS to guide precise therapeutic strategies. Methods: We analyzed RNA-seq data obtained from tumor tissues from 102 OS patients using a non-negative matrix factorization algorithm (NMF) to classify the tumors into three subtypes: S1, S2, and S3. Differential gene expression was evaluated using DESeq2, followed by functional enrichment analysis with clusterProfiler and CancerHallmarks. The tumor microenvironment was assessed through ESTIMATE and CIBERSORT, and drug sensitivity was predicted using OncoPredict. SAOS-2 and MG63 cells, representing the S1 subtype, were used in the viability essays to determine the effect of hesperidin, a natural phenolic compound noted for its anti-cancer potential, alone and in combination with doxorubicin and 5-fluorouracil. Results: This study revealed three OS subtypes: S1 was enriched in cell cycle regulation, vesicular transport, and RNA metabolism while S2 and S3 were enriched in pathways related to extracellular matrix organization and protein translation, respectively. S1 displayed high tumor purity, significant chemoresistance, and overexpression of KIF20 A, correlating with poor prognosis. AURKB, a hesperidin target, was implicated in S1 pathogenesis. In vitro, hesperidin significantly reduced the viability of SAOS-2 and MG63 cells and enhanced doxorubicin efficacy. Conclusions: Our findings support the molecular subclassification of OS, emphasizing subtype-specific mechanisms of tumor progression and chemoresistance, with hesperidin offering potential as a therapeutic adjunct for high-risk OS patients.
Background: Osteosarcoma (OS) is a highly aggressive primary bone malignancy, for which treatment and prognosis remain unchanged for three decades. This study aimed to delineate molecular subtypes of early-stage, treatment-naive OS to improve molecular stratification and guide precise therapeutic strategies. Methods: The top 10% of the most variable genes of 102 OS tumour tissues were used in NMF to classify the tumours into three subtypes, S1, S2, and S3. Differential expression analysis was carried out using DESeq2 and functional enrichment analysis using clusterProfiler and CancerHallmarks. Tumor microenvironment composition was estimated through ESTIMATE and CIBERSORT, and drug sensitivity prediction using OncoPredict. NMF was also applied to RNA-seq data from 19 osteosarcoma cell lines and DEGs between the groups were correlated with the DEGs from patients' subtypes. SAOS-2, representing S1, was used in the viability assays to determine the effects of hesperidin, alone or in combination with doxorubicin and 5-fluorouracil. Results: S1 was enriched in cell cycle regulation, vesicular transport, and RNA metabolism with high tumor purity and high resistance to chemotherapeutics. S2 and S3 were enriched in extracellular matrix organization and protein translation pathways, respectively. KIF20A was significantly overexpressed gene indicating a poor prognosis of S1. AURKB, a hesperidin target, was found as an important gene for the pathogenesis of S1. Hesperidin significantly reduced SAOS-2 cell viability and enhanced the efficacy of doxorubicin. Conclusions: Our results offer a strong molecular basis for OS subclassification, highlighting subtype-specific mechanisms of tumour progression and chemoresistance. Our findings support the prospect of customized therapeutic approaches, with hesperidin being a promising co-adjuvant to improve the prognosis of high-risk OS patients.
Osteosarcoma is an aggressive malignancy whose treatment has changed little over the past decades, and outcomes remain poor. Although transcriptomic studies have provided insights into osteosarcoma biology, many include metastatic or post-treatment tumours, potentially obscuring transcriptional programs associated with intrinsic tumour aggressiveness. To address this limitation, we analysed transcriptomic profiles exclusively from treatment-naive, non-metastatic osteosarcoma patients to reconstruct prognostic transcriptional regulons associated with outcome. We identified distinct transcriptional programs associated with favourable and unfavourable outcomes. Tumours linked to poor prognosis were characterized by coordinated proliferative and metabolic transcriptional programs controlled by three regulatory hubs: CTCF, E2F4, and SP1, whose regulon enrichments showed strong associations with patient survival. To explore whether these regulatory networks could be pharmacologically modulated, molecular docking and dynamics simulations were performed, revealing potentially stable interactions between the hesperidin and the DNA-binding domains of these key transcription factors. Transcriptomic analysis of osteosarcoma cells treated with hesperidin revealed alterations in the identified regulons’ composition and decreased transcription factor activity. Together, these findings identify a transcriptional regulatory architecture underlying aggressive osteosarcoma, revealing novel prognostic biomarkers and suggesting that pharmacological modulation of master regulators such as CTCF, E2F4, and SP1, may represent a strategy to target transcriptional vulnerabilities in this malignancy.